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SUMMARY – Th e purpose of this review is to present contemporary measures for preventing the 
increase in preovulatory progesterone (P) and its adverse eff ects on ovarian stimulation in in vitro 
fertilization (IVF). For the last 20 years, the increase of preovulatory P has been a topic of numerous 
discussions because its role is not fully understood in terms of its impact on pregnancy outcome after 
IVF. Some studies failed to establish a connection between the preovulatory P increase and successful 
IVF outcome regardless of the level of P, while, conversely, most other studies have reported on adverse 
eff ects of elevated P concentrations. Current strategies to prevent the increase in preovulatory P in-
clude an individualized approach with the use of mild stimulation protocols and early application of 
human chorionic gonadotropin for ovulation induction among good responders, delay in the transfer 
of fresh embryos from 3rd to 5th day, and cryopreservation of all embryos with the thawed embryo 
transfer in the natural cycle. Nevertheless, further studies are needed to confi rm the current preventive 
methods or enable the application of new strategies in order to lower or eliminate the detrimental 
eff ects of preovulatory P rise during ovarian stimulation in IVF.
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Introduction
Elevated preovulatory serum progesterone (P) is 
frequently ascertained during the late follicular phase 
at the end of ovarian stimulation on the day of ovula-
tion triggering with human chorionic gonadotropin 
(hCG) during the in vitro fertilization (IVF) cycle. 
Th e incidence of premature P rise varies widely from 
13% to 71% depending on defi nition, cut-off  level of P, 
stimulation protocols and population characteristics1. 
Th e presence of premature luteinizing hormone (LH) 
surge during ovarian stimulation has been previously 
correlated with preovulatory P rise and it has been 
constantly associated with reduced pregnancy rates2. 
In order to prevent premature LH rise and conse-
quently premature P rise, gonadotropin-releasing hor-
mone (GnRH) analogues have been introduced. Al-
though the signifi cance of GnRH analogues in the 
prevention of preovulatory P rise has been proven, 
higher P levels have been recorded in approximately 
35% of GnRH agonist cycles and 38% of GnRH an-
tagonist cycles3.
Th e ovarian response to follicle stimulating hor-
mone (FSH) in recombinant (rec)-FSH/GnRH an-
tagonist cycles has been associated with the risk of P 
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elevation. Furthermore, a direct correlation between 
premature P rise and estradiol (E2) levels and the 
number of follicles on the day of hCG administration 
has been widely confi rmed. Th e association between 
the high E2 and premature P elevation could be ex-
plained by an excess of proliferating granulosa cells 
that can lead to an increased P production4. According 
to the two-cell, two-gonadotropin theory and the fact 
that excessive FSH stimulation may increase the pro-
duction of P, the inclusion of LH activity products in 
stimulation protocols to counterbalance the eff ect of 
FSH may help reduce the risk of late follicular P in-
creases5. However, a systematic review of several stud-
ies comparing FSH administration alone or in combi-
nation with LH activity products could not demon-
strate any signifi cant eff ect of ‘LH activity’ on serum 
preovulatory P elevation. Th erefore, the major deter-
mining factor for the risk of P rise at the time of hCG 
administration remains the degree of ovarian response 
to FSH6. However, early addition of increasing doses 
of hCG (0, 50, 100 and 150 IU) from the beginning of 
ovarian stimulation in combination with rec FSH + 
GnRH antagonist was associated with an increased 
risk of P elevation7. Furthermore, it appears that the 
choice of GnRH analogue has an impact on the risk of 
P elevation because preovulatory P levels were higher 
in women treated with GnRH agonist as compared 
with GnRH antagonist. Th ese diff erences can be ex-
plained by stronger ovarian response to FSH as the 
main driver of P output and by higher endogenous LH 
concentration during the last few days of stimulation 
in favor of GnRH agonist8,9. It appears that endoge-
nous LH in the late follicular phase acts positively on 
P secretion and women treated with GnRH agonist 
protocols are more prone to P elevation10.
Since the early 1990s, there has been an ongoing 
debate in more than 60 studies in women undergoing 
ovarian stimulation with controversial conclusions re-
garding the impact of preovulatory P on IVF outcome. 
Several previous and recent studies failed to demon-
strate any negative eff ect of P rise10-12. Th e fi rst meta-
analysis of 12 studies, published in 2007, has reported 
that there was a nonsignifi cant negative association 
between P elevation and pregnancy rate in women 
with GnRH analogues and gonadotropins12. However, 
the second meta-analysis from 2012 focused on wom-
en using GnRH antagonists and gonadotropins (fi ve 
studies) states that P elevation on the day of hCG ad-
ministration is associated with a signifi cantly decreased 
probability of clinical pregnancy per cycle13. Similarly, 
in the third meta-analysis from 2013 of over 60 000 
fresh IVF cycles it was found that P elevation on the 
day of hCG was associated with a signifi cantly de-
creased probability of pregnancy in women, whatever 
the GnRH analogue used. Th e thresholds of serum P 
on the day of hCG administration were arbitrarily 
chosen from 0.4 ng/mL to 3 ng/mL and the strongest 
eff ect size of P elevation for achievement of pregnancy 
was observed with P thresholds between 1.5 ng/mL 
and 1.75 ng/mL14. Several recent studies also estab-
lished that P elevation on the day of hCG administra-
tion could be associated with a risk of reduced implan-
tation rate. Despite the use of diff erent thresholds of 
serum P, the optimal P threshold over which a detri-
mental eff ect on IVF outcome might be observed has 
been estimated to 1.5 ng/mL and this threshold has 
been commonly used10,15,16. It seems that the P thresh-
old in women using GnRH agonists is dependent on 
the degree of the ovarian response because in poor re-
sponders, the P threshold associated with a lower 
pregnancy rate was estimated at 1.5 ng/mL, in patients 
with normal ovarian response 1.75 ng/mL and in high 
responders 2.25 ng/mL17. Consequently, in patients 
treated with rec FSH and GnRH antagonists, P eleva-
tion does not compromise pregnancy rates in high re-
sponders, although its incidence increases with ovarian 
response and elevated P at a threshold of 1.5 ng/mL is 
independently associated with a decreased chance of 
pregnancy in low-to-normal responders. Th erefore, it 
seems that the detrimental eff ect of P elevation on the 
implantation rate could be compensated for by an in-
creased yield of high-quality oocytes18. Interestingly, 
the duration of P elevation could have a stronger im-
pact on cycle outcome than the absolute serum P con-
centration on the day of hCG. Th e clinical pregnancy 
rate is signifi cantly inversely correlated with the dura-
tion of premature serum P elevation above the cut-off  
value of 1.0 ng/mL, whatever the protocol used and 
the intensity of the ovarian response19. It seems that 
the use of a multivariable analysis is the proper way of 
assessing the adverse eff ect of preovulatory P elevation 
on live birth rates, when compared with the bivariate 
analysis that was used in most of the studies that failed 
to identify the detrimental eff ect in fresh IVF cycles20.
Since preovulatory P rise during ovarian stimula-
tion is not associated with any signifi cant changes in 
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either oocyte or embryo quality, it is now convincingly 
accepted that P prematurely opens the window of im-
plantation and modifi es endometrial receptivity, lead-
ing to defective implantation and mainly contributing 
to the decreased pregnancy rate14. Indeed, any 3-day 
advancement in endometrial receptivity assessed by 
endometrial biopsy at the time of oocyte retrieval re-
sults in a signifi cant decrease in implantation rate, pre-
sumably related to P elevation21,22. However, direct 
evidence for an eff ect of P rise on the endometrium 
has been provided by the altered gene expression pro-
fi le in a recent functional genomics analysis23,24. Since 
the majority of published studies demonstrated a det-
rimental eff ect of preovulatory P elevation which con-
tributes to a decreased pregnancy rate, the purpose of 
this review is to analyze current preventive strategies 
that may improve pregnancy outcome following IVF.
Prevention of Preovulatory Progesterone 
Elevation
Mild ovarian stimulation protocols are associated 
with lower E2 levels and therefore may be useful in the 
prevention of premature P rise due to strong correla-
tion between ovarian response and preovulatory P 
rise25, which may be achieved with limited gonadotro-
pins or with alternatives such as anti-estrogens or aro-
matase inhibitors since they reduce the dose of gonad-
otropins required for stimulation and keep estrogen 
levels low26. Th ere are limited clinical data available 
concerning the use of aromatase inhibitors in IVF 
treatment. Up to date, only three randomized con-
trolled trials involving a total of 80 women studied the 
use of aromatase inhibitors in IVF27. However, new 
studies yielded promising results on the benefi t of 
 aromatase inhibitor use in terms of ovarian stimulation 
for IVF28,29. Although mild stimulation is correlated 
with a reduced risk of premature P rise, lower preg-
nancy rates per cycle, fewer embryos for cryopreserva-
tion and still not available individualized FSH-dosing 
algorithms have been reported27. Moreover, it is im-
portant to consider each patient’s general condition 
including age, ovarian reserve, embryo grading and the 
capacity of frozen/thawed embryo transfer when mild 
protocols are used for stimulation30.
An earlier hCG trigger, when follicles reach a di-
ameter of 15-16 mm, has been suggested as a strategy 
for preventing premature P rise. It has been suggested 
that earlier hCG trigger should take place when ≥3 
follicles of ≥16 mm diameter are present on ultraso-
nography31. However, this early trigger has been asso-
ciated only with lower preovulatory P but not with 
better ongoing pregnancy rates32. In order to avoid 
premature P rise and its detrimental eff ect on IVF out-
come, earlier trigger in high responders is more suit-
able as compared with normal and poor responders31,33. 
Due to the potential predictive role of E2 concentra-
tions for premature P rise, fi nal oocyte maturation can 
be triggered when the E2 concentration reaches the 
point of having a risk of preovulatory P rise34.
One of the strategies that have been suggested to 
overcome the detrimental eff ect of advanced endome-
trial maturation is to enable endometrial recovery be-
fore transfer. Numerous studies investigated the bene-
fi t of day 5 compared to day 3 embryo transfer (ET)35-
37; increased probability of pregnancy with day 5 ET 
was recorded in 2 independent trials36,38. In other 
words, a higher rate of early pregnancy loss was re-
corded after day 3 single ET as compared with day 5 
single blastocyst transfer in GnRH antagonist stimu-
lated IVF cycles. Two diff erent systematic reviews and 
meta-analysis independently confi rmed previous fi nd-
ings; improved IVF outcome was associated with day 
5 ET and not with day 3 ET38,39. Analyzing both de-
velopmental stage and fragmentation rate, the implan-
tation potential of advanced blastocysts was infl uenced 
by developmental stage on day 5 and fragmentation 
rate on day 3 ET40. Lower implantation rate on day 3 
ET is most likely associated with disturbed embryo-
endometrium synchrony in terms of high preovulatory 
P. Furthermore, as the endometrium seems to be re-
covered from the supraphysiological P values on day 5, 
a better implantation rate is quite expected with day 5 
single blastocyst transfer41. However, only a few stud-
ies failed to confi rm the preference of day 5 ET as a 
potential strategy to overcome the deleterious eff ect of 
elevated P on IVF pregnancy outcome. Th erefore, bet-
ter embryo implantation and live birth rate could not 
be confi rmed on day 5 fresh ET in terms of the rise of 
serum P levels ≥2.0 ng/mL on the day of hCG admin-
istration in cycles with GnRH agonists42. Similarly, a 
study from 2013 failed to demonstrate the preference 
of day 5 ET as a strategy to overcome the detrimental 
eff ect of P rise on IVF pregnancy outcome33. Never-
theless, as the majority of studies yielded better im-
plantation rate and IVF pregnancy outcome with day 
Emina Ejubović et al. Preovulatory progesterone and in vitro fertilization
456 Acta Clin Croat, Vol. 55, No. 3, 2016
5 single blastocyst transfer as compared with day 3 
single ET, the selection of blastocyst transfer as a strat-
egy for overcoming the adverse eff ect of high preovu-
latory P seems to be quite justifi ed36,37,41.
Elective cryopreservation of all embryos with sub-
sequent transfer in a natural cycle or during ovulation 
induction has been proposed as a solution to avoid the 
negative eff ect of high preovulatory P on IVF out-
come, as well as in the prevention of ovarian hyper-
stimulation syndrome42,43. Indeed, various studies yield-
ed signifi cantly higher ongoing and clinical pregnancy 
rates when frozen ET was used as compared with fresh 
ET44-46. It seems that the adverse eff ect of P elevation 
on endometrium in terms of IVF outcome could be 
overcome by frozen-thawed embryo transfer (FET) in 
a later non-stimulated cycle, since the embryo-endo-
metrium synchrony is thus re-established, although 
poor quality embryos could not be eliminated through 
the utilization of cryopreservation46. In the past de-
cade, the number of frozen-thawed embryo transfer 
cycles per started IVF cycle has increased steadily and 
at the same time the percentage of frozen-thawed em-
bryo transfers that resulted in live births has increased. 
Currently, cryopreservation of human embryos is more 
important than ever for the cumulative pregnancy rate 
after IVF. It seems that freeze-all strategy, in which 
all embryos are frozen and no fresh transfer is con-
ducted, has been proven to increase success rates in 
IVF cycles47.
Conclusion
Current strategies in the prevention of preovulato-
ry P rise include an individualized approach with the 
use of mild stimulation protocols with intensive moni-
toring of folliculogenesis and earlier use of hCG for 
ovulation induction in high responders. However, to 
avoid the negative endometrial eff ects of P rise, it 
should be useful to delay ET from day 3 to day 5. Fi-
nally, the most appropriate choice would be to cancel 
fresh ET and freeze all embryos with FET in the nat-
ural cycle. However, there is the need for further re-
search which would confi rm the current preventive 
methods or enable the application of new strategies in 
order to lower or eliminate the detrimental eff ects of 
preovulatory P rise during ovarian stimulation in IVF 
procedure.
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Sažetak
SUVREMENE PREVENCIJSKE STRATEGIJE PORASTA PREDOVULACIJSKOG PROGESTERONA 
TIJEKOM STIMULACIJE JAJNIKA U POSTUPKU IZVANTJELESNE OPLODNJE
E. Ejubović, M. Kasum, P. Stanić, J. Juras, E. Čehić i S. Orešković
Svrha ovoga preglednog članka je prikazati suvremene mjere za prevenciju porasta predovulacijskog progesterona (P) i 
njegovih nepovoljnih učinaka kod stimulacije jajnika u postupku izvantjelesne oplodnje. Unatrag 20-ak godina porast pred-
ovulacijskog P tema je brojnih rasprava, jer njegova uloga nije u potpunosti razjašnjena u pogledu utjecaja na ishod trudnoće 
nakon postupka izvantjelesne oplodnje. Neka istraživanja nisu utvrdila nikakvu povezanost između porasta predovulacijskog 
P u odnosu na uspješnost postupka izvantjelesne oplodnje neovisno o razini P, dok nasuprot tome, većina drugih istraživanja 
izvješćuje o nepovoljnim učincima povišene koncentracije P. Suvremene strategije u prevenciji porasta predovulacijskog P 
uključuju individualizirani pristup primjenom blažih stimulacijskih protokola te raniju primjenu humanog korionskog gona-
dotropina za indukciju ovulacije kod bolesnica koje dobro reagiraju na stimulaciju, odgodu prijenosa svježih zametaka s 3. na 
5. dan i krioprezervaciju svih zametaka uz transfer odmrznutih embrija u prirodnom ciklusu. Neophodna su daljnja istraži-
vanja koja će potvrditi postojeće prevencijske metode ili omogućiti primjenu novih strategija, sa svrhom onemogućavanja 
nepovoljnog utjecaja porasta predovulacijskog P na ishod trudnoće nakon postupka izvantjelesne oplodnje.
Ključne riječi: Ženska osoba; Fertilizacija, in vitro; Progesteron – biosinteza; Ovulacija, indukcija; Zametak, transfer; Kriopre-
zervacija
